---
title: "AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295652271.md"
description: "Needham analyst Gil Blum reaffirmed a Buy rating on AbSci (ABSI) with an $11 price target, citing the advancement of its lead program ABS-201 for hair loss and a strong cash position of $201M. The analyst views the upcoming 2026 clinical data as a key catalyst. TD Cowen also maintained a Buy rating."
datetime: "2026-08-12T10:45:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295652271.md)
  - [en](https://longbridge.com/en/news/295652271.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295652271.md)
generator: "portal-rs"
---

# AbSci: Buy Rating Reaffirmed as ABS-201 Hair-Loss Program Advances; $11 Price Target Maintained

Needham analyst Gil Blum has maintained their bullish stance on ABSI stock, giving a Buy rating yesterday.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Gil Blum has given his Buy rating due to a combination of factors related to AbSci’s lead program and financial position. He views ABS-201 for pattern hair loss as the core driver of shareholder value, with a key 13-week interim data read from randomized multiple-ascending-dose cohorts expected in the second half of 2026, providing a meaningful clinical catalyst.

Blum highlights the innovative prolactin-blocking mechanism, noting that even early, directional signs of hair regrowth could be materially positive, especially since ABS-201 could be used alongside existing treatments like finasteride and oral minoxidil. Coupled with AbSci’s solid cash balance of $201M after its recent $100M raise, which should fund operations into the second half of 2028, he sees sufficient runway to reach value-inflecting milestones and thus reiterates his $11 price target and Buy rating.

According to TipRanks, Blum is a 5-star analyst with an average return of 16.3% and a 46.98% success rate. Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Fate Therapeutics, and Cartesian Therapeutics.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)
- [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md)
- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [RNAC.US](https://longbridge.com/en/quote/RNAC.US.md)

## Related News & Research

- [Absci (ABSI) Could Be 32% Undervalued Following ABS 201 Data And Earnings](https://longbridge.com/en/news/295686913.md)
- [Denison Mines (DNN) Receives a Buy from Roth MKM](https://longbridge.com/en/news/296056406.md)
- [Barclays Sticks to Its Buy Rating for Prosus (PROSF)](https://longbridge.com/en/news/296063490.md)
- [Two quantum computing stocks are starting to pull ahead of the pack](https://longbridge.com/en/news/296224723.md)
- [DBS Keeps Their Buy Rating on Geely Automobile Holdings (GELYF)](https://longbridge.com/en/news/296067847.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**